BR112017007011A2 - compostos de metil-piperidina úteis para inibir a prostaglandina e2 sintase-1 microssômica - Google Patents

compostos de metil-piperidina úteis para inibir a prostaglandina e2 sintase-1 microssômica

Info

Publication number
BR112017007011A2
BR112017007011A2 BR112017007011A BR112017007011A BR112017007011A2 BR 112017007011 A2 BR112017007011 A2 BR 112017007011A2 BR 112017007011 A BR112017007011 A BR 112017007011A BR 112017007011 A BR112017007011 A BR 112017007011A BR 112017007011 A2 BR112017007011 A2 BR 112017007011A2
Authority
BR
Brazil
Prior art keywords
microsomal
compounds useful
methyl piperidine
piperidine compounds
inhibiting prostaglandin
Prior art date
Application number
BR112017007011A
Other languages
English (en)
Other versions
BR112017007011B1 (pt
Inventor
M Warshawsky Alan
Schulenburg York Jeremy
Marie Partridge Katherine
Allen Schiffler Matthew
Joseph Fisher Matthew
Rudolph Manninen Peter
Lee Kuklish Steven
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017007011(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112017007011A2 publication Critical patent/BR112017007011A2/pt
Publication of BR112017007011B1 publication Critical patent/BR112017007011B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

a presente invenção proporciona compostos de fórmula (1), ou um seu sal farmaceuticamente aceitável, fórmula (1), em que r, r1 e g são conforme descritos neste documento; métodos de preparar os compostos; e uso dos compostos para tratar a dor e/ou a inflamação associadas com a artrite ou a osteoartrite.
BR112017007011-1A 2014-10-29 2015-10-22 Compostos de metil-piperidina, composição farmaceuticamente aceitável que o compreende e seu uso BR112017007011B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462072196P 2014-10-29 2014-10-29
US62/072,196 2014-10-29
PCT/US2015/056960 WO2016069376A1 (en) 2014-10-29 2015-10-22 Novel methyl-piperidine compounds useful for inhibiting microsomal prostaglandin e2 synthase-1

Publications (2)

Publication Number Publication Date
BR112017007011A2 true BR112017007011A2 (pt) 2017-12-26
BR112017007011B1 BR112017007011B1 (pt) 2023-05-23

Family

ID=

Also Published As

Publication number Publication date
EA032428B1 (ru) 2019-05-31
LT3230278T (lt) 2020-03-10
SI3230278T1 (sl) 2020-02-28
ES2773439T3 (es) 2020-07-13
WO2016069376A1 (en) 2016-05-06
PL3230278T3 (pl) 2020-06-01
US20180250282A1 (en) 2018-09-06
EP3230278B1 (en) 2019-12-11
NZ730724A (en) 2018-09-28
HRP20200216T1 (hr) 2020-05-15
JP6393830B2 (ja) 2018-09-19
US9962375B2 (en) 2018-05-08
MX2017005659A (es) 2017-06-26
CN107074829B (zh) 2020-11-13
ZA201702198B (en) 2018-12-19
CL2017001017A1 (es) 2017-12-11
KR20170055025A (ko) 2017-05-18
AR102362A1 (es) 2017-02-22
CA2963321A1 (en) 2016-05-06
PT3230278T (pt) 2020-02-20
EP3230278A1 (en) 2017-10-18
TW201627285A (zh) 2016-08-01
AU2015339644B2 (en) 2018-03-29
CY1122534T1 (el) 2021-01-27
HUE047895T2 (hu) 2020-05-28
TWI605039B (zh) 2017-11-11
CA2963321C (en) 2020-01-14
RS59783B1 (sr) 2020-02-28
DK3230278T3 (da) 2020-01-20
EA201790766A1 (ru) 2017-12-29
US20170326128A1 (en) 2017-11-16
CN107074829A (zh) 2017-08-18
AU2015339644A1 (en) 2017-04-20
JO3581B1 (ar) 2020-07-05
JP2017537073A (ja) 2017-12-14
KR101898829B1 (ko) 2018-09-13

Similar Documents

Publication Publication Date Title
BR112018069612A2 (pt) compostos de pirroltriazina como inibidores de tam
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
CL2017001017A1 (es) Nuevos compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
CL2017001050A1 (es) Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
CY1120378T1 (el) Υποκατεστημενα παραγωγα του διφαινυλο βουτανοϊκου φωσφονικου οξεος ως αναστολεις νερ (ουδετερης ενδοπεπτιδασης)
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112016017996A2 (pt) 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso
BR112017009470A2 (pt) síntese de copanlisib e seu sal de di-hidrocloreto.
BR112017001334A2 (pt) compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende
EA201690844A1 (ru) Ингибиторы gsk-3
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
BR112017009471A2 (pt) síntese de copanlisib e seu sal de di-hidrocloreto.
BR112017008794A2 (pt) inibidores de di-heteroaril histona desacetilase e seu uso em terapia
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
CR20170513A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap).
BR112014018712A8 (pt) Derivados de morfolinila úteis como inibidores de mogat-2
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
BR112018015191A2 (pt) compostos de 6,7-di-hidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
BR112018012325A2 (pt) métodos para a preparação de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina substituída

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/10/2015, OBSERVADAS AS CONDICOES LEGAIS